Method for preparing polygonum paleaceum dry extract by hot water extraction and ethanol precipitation and/or its purification part

Abstract

The invention discloses a preparation method of the boiled and alcohol-precipitated dry extract of Rhizoma japonicus and / or its purified part. Put Herba blood and pure water in a container, reflux in a water bath at 100°C for 30-90 minutes, add alcohol to the filtrate obtained by suction filtration, place it at 0-8°C until the filtrate and alcohol are fully mixed, and then pump Filter to get the alcohol-containing filtrate, then place it under reduced pressure at 70-85°C to concentrate the extract of Dracaena japonicus and boil it in water, then concentrate it to 0.1-0.4 times the original volume, then distill off the ethanol to obtain the residue, and use distilled water Dissolve the residue, filter out the insoluble matter to obtain the filtrate, pass the filtrate through a strong acid cationic resin column, wash with water until colorless, then elute with 3N NH4OH, collect the ammonia eluate, concentrate to obtain a paste, and wash the paste Put it on a silica gel column, and elute with acetone-methanol to obtain the dry extract of D. japonicus. Concentrate the dried extract of D. japonicus in water and alcohol until a white powder precipitates out to obtain a purified part.

Description

technical field [0001] The invention relates to a preparation method of boiled and alcohol-precipitated dry extract of Rhizoma japonicus and / or its purified part, which belongs to the field of pharmacy. Background technique [0002] At present, many antiviral drugs have limited their clinical application due to toxic side effects and long-term drug resistance. For example, amantadine and its structural derivative methylamantadine, which are commonly used in clinical treatment of influenza, have neurotoxicity and are prone to Deficiencies such as drug-resistant strains and ineffectiveness against influenza B virus; currently the only drug approved by the FDA for the prevention and treatment of respiratory syncytial virus infection is ribavirin, but it has bone marrow cytotoxicity when it is administered intravenously and passes through the respiratory tract through aerosol Leukopenia occurs when given in a small amount, and side effects such as headache and irreversible anemi...

AI Technical Summary

Problems solved by technology

[0002] At present, many antiviral drugs have limited their clinical application due to toxic side effects and long-term drug resistance. For example, amantadine and its structural derivative methylamantadine, which are commonly used in clinical treatment of influenza, have neurotoxicity and are prone to Deficiencies such as drug-resistant strains and ineffectiveness against influenza B virus; currently the only drug approved by the FDA for the prevention and treatment of respiratory syncytial virus infection is ribavirin, but it has bone marrow cytotoxicity when it is administered intravenously and passes through the respiratory tract through aerosol Leukopenia occurs when a small amount is given, and side effects such as headache and irreversible anemia can be caused when the dose is too large; the anti-herpes virus drug acyclovir can easily cause drug resistance of herpes simplex virus, resulting in persistent incidence of respiratory virus infection